current glp-1 drugs Indications for GLP-1/GIP RA Summary Sheet and Beyond! List of approved and pending

November 2023 : Eli Lilly received US FDA approval for ZEPBOUND, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors

These agents activate AMP-activated protein kinase signaling, leading to suppression of mammalian target of rapamycin complex 1 activity and reduced expression of pro-inflammatory cytokines and adhesion molecules [29]

Cost: $199$349 per month without insurance, depending on dose

Pfizer sought to enjoin the competing offer and insisted the shareholder vote set for mid-November proceed under the original agreement ( [4] )

View at Publisher | View at Google Scholar Drucker DJ

J Cereb Blood Flow Metab (2011) 31:1696705